Results 11 to 20 of about 2,138,197 (387)

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

New England Journal of Medicine, 2021
BACKGROUND The prognosis of patients with early relapsed or refractory large B-cell lymphoma after the receipt of first-line chemoimmunotherapy is poor.
F. Locke, D. Miklos, C. Jacobson, M. Perales, M. Kersten, O. Oluwole, A. Ghobadi, A. Rapoport, J. McGuirk, J. Pagel, J. Muñoz, U. Farooq, T. van Meerten, P. Reagan, A. Sureda, I. Flinn, P. Vandenberghe, K. Song, M. Dickinson, M. Minnema, P. Riedell, L. Leslie, S. Chaganti, Yin Yang, S. Filosto, J. Shah, M. Schupp, C. To, P. Cheng, L. Gordon, J. Westin   +30 more
semanticscholar   +1 more source

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

New England Journal of Medicine, 2021
BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP.
H. Tilly, F. Morschhauser, L. Sehn, J. Friedberg, M. Trněný, J. Sharman, C. Herbaux, J. Burke, M. Matasar, S. Rai, K. Izutsu, N. Mehta-Shah, L. Obéric, A. Chauchet, W. Jurczak, Yuqin Song, R. Greil, Larysa Mykhalska, J. Bergua-Burgues, M. Cheung, A. Pinto, H. Shin, G. Hapgood, E. Munhoz, P. Abrisqueta, J. Gau, J. Hirata, Yanwen Jiang, M. Yan, Calvin Lee, C. Flowers, G. Salles   +31 more
semanticscholar   +1 more source

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

New England Journal of Medicine, 2022
BACKGROUND The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells.
M. Dickinson, C. Carlo-Stella, F. Morschhauser, E. Bachy, P. Corradini, G. Iacoboni, C. Khan, T. Wróbel, F. Offner, M. Trněný, Shang-Ju Wu, G. Cartron, M. Hertzberg, A. Sureda, D. Pérez-Callejo, L. Lundberg, J. Relf, M. Dixon, E. Clark, K. Humphrey, M. Hutchings   +20 more
semanticscholar   +1 more source

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Journal of Clinical Oncology, 2022
PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells.
C. Thieblemont, T. Phillips, H. Ghesquières, C. Cheah, M. Clausen, D. Cunningham, Y. Do, T. Feldman, R. Gasiorowski, W. Jurczak, Tae Min Kim, D. Lewis, M. van der Poel, M. Poon, Mariana Cota Stirner, N. Kilavuz, Christopher W Chiu, Meng‐Yu Chen, M. Sacchi, B. Elliott, T. Ahmadi, M. Hutchings, P. Lugtenburg   +22 more
semanticscholar   +1 more source

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

New England Journal of Medicine, 2023
BACKGROUND In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, as ...
J. Westin, O. Oluwole, M. Kersten, D. Miklos, M. Perales, A. Ghobadi, A. Rapoport, A. Sureda, C. Jacobson, U. Farooq, T. van Meerten, M. Ulrickson, M. Elsawy, L. Leslie, S. Chaganti, M. Dickinson, K. Dorritie, P. Reagan, J. McGuirk, K. Song, P. Riedell, M. Minnema, Yin Yang, S. Vardhanabhuti, S. Filosto, P. Cheng, Shilpa A. Shahani, M. Schupp, C. To, F. Locke   +29 more
semanticscholar   +1 more source

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

New England Journal of Medicine, 2019
BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel
S. Schuster, M. Bishop, C. Tam, E. Waller, P. Borchmann, J. Mcguirk, U. Jäger, S. Jaglowski, C. Andreadis, J. Westin, I. Fleury, V. Bachanova, R. Foley, Joy P. Ho, S. Mielke, J. Magenau, H. Holte, Serafino Pantano, L. Pacaud, R. Awasthi, J. Chu, Ö. Anak, G. Salles, R. Maziarz   +23 more
semanticscholar   +1 more source

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Intramural great vessel lymphoma presenting as thrombus in an aortic aneurysm

Human Pathology: Case Reports, 2019
Intravascular large B-cell lymphoma (IVLBCL) is a subtype of extranodal B-cell lymphoma with growth limited to the lumina of small vessels. Intramural great vessel lymphoma (IMGVL), on the contrary, is extremely rare and there have been only two reported
Sameera Rashid, Shehab F. Mohamed, Mohamed Yassin, Laith F. Tbishat, Hassan Al-Thani, Issam Albozom   +5 more
doaj   +1 more source

Intravascular large B‐cell lymphoma in renal cell carcinoma incidentally detected by robot‐assisted partial nephrectomy

IJU Case Reports, 2022
Introduction Intravascular large B‐cell lymphoma is a rare and aggressive type of extranodal large B‐cell lymphoma. Although intravascular large B‐cell lymphoma can invade various organs, renal involvement has been rarely reported. Synchronous occurrence
Michio Noda, Yutaka Enomoto, Yukari Shirasugi, Sumiyo Ando, Yukimasa Matsuzawa, Haruki Kume   +5 more
doaj   +1 more source

Emerging targets in human lymphoma: targeting the MYD88 mutation [PDF]

, 2016
B cell neoplasms co-opt the molecular machinery of normal B cells for their survival. Technological advances in cancer genomics has significantly contributed to uncovering the root cause of aggressive lymphomas, revealing a previously unknown link ...
Horikawa, Keisuke, Jeelall, Yogesh S., Wang, James Q.   +2 more
core   +1 more source